The cluster headache market size is expected to increase from USD 0.86 billion in 2025 to USD 0.92 billion in 2026 and reach USD 1.26 billion by 2031, growing at a CAGR of 6.56% over 2026-2031. This report is Segmented by Diagnosis Type (Clinical Assessment, and More), Treatment Type (Acute, and More), Drug Class (Triptans, and More), Route of Administration (Oral, Injectable, and More), Distribution Channel (Hospital, Retail, Online, and More), Patient Type (Episodic, Chronic), and Geography (North America, Europe, Asia-Pacific, and More). Market Forecasts are Provided in Terms of Value (USD).
Other drivers and restraints analyzed in the detailed report include:
In 2025, acute treatments, led by oxygen and subcutaneous sumatriptan, accounted for 65.44% of the revenue. Preventive therapies are projected to grow at a 7.60% CAGR through 2031, as CGRP mAbs shift the clinical approach toward long-term attack suppression. Corticosteroid bridges and occipital nerve blocks serve as transitional solutions but lack the scale of acute and preventive segments. GammaCore's dual functionality in both acute and preventive treatment is driving interest in hybrid therapeutic strategies.
In Europe, the market is driven by harmonized clinical guidelines and a strong emphasis on cost-effectiveness. The endorsement of vagus-nerve stimulation by regulatory bodies has influenced reimbursement policies across key markets, including Germany, France, and Nordic countries. Moreover, Europe is positioning itself as a leader in advanced medical technologies, with initiatives such as the development of AI-enabled closed-loop neuromodulation systems. These advancements are expected to enhance treatment outcomes, improve patient care, and drive the adoption of innovative solutions across the region.
The Asia-Pacific region is undergoing a transition from fragmented regulatory frameworks to unified standards under ASEAN and ICH guidelines. While South Korea's step-edit policies present barriers to the immediate adoption of biologics, Japan's stringent two-year post-marketing surveillance process generates robust safety data, fostering greater confidence in the long-term use of these treatments. In China, although CGRP monoclonal antibodies are not yet included in the National Reimbursement Drug List, pilot programs in select cities are exploring innovative value-based contracting models. These initiatives could pave the way for broader adoption and integration of advanced therapies, driving growth and improving patient outcomes in the region.
Global Cluster Headache Market Trends and Insights
Expansion of Targeted Biologics & Novel Therapeutics
Galcanezumab, the only CGRP monoclonal antibody approved for episodic cluster headaches, demonstrated a 71.4% responder rate by week 3 in pivotal studies. Organon expanded its commercialization efforts to 11 new markets in 2024 through a USD 22.5 million deal, reflecting payers' willingness to reimburse orphan indications.' The 2025 ALLEVIATE trial for eptinezumab did not meet its primary endpoint but indicated potential delayed benefits, suggesting a shift by payers toward sustained-response benchmarks. Fremanezumab’s futility stop highlights the variability in biologics, reinforcing the importance of attack-frequency-based enrichment arms. A 2026 meta-analysis confirmed superior short-term efficacy in episodic diseases, guiding future trial designs toward subtype stratification.Home-Use Non-Invasive Vagus Nerve Stimulation Uptake
GammaCore, after receiving U.S. clearance for acute use in 2017 and preventive use in 2018, was endorsed in 2019 for its cost-saving potential, with projected annual savings of GBP 450 (USD 570) per patient. The PREVA study demonstrated a reduction of 5.9 attacks per week compared to 2.1 with a sham, along with a 57% decrease in abortive medication usage. Salvia BioElectronics secured USD 60 million in 2025 to develop ultra-thin implants with AI-controlled stimulation, achieving Breakthrough Device status. Europe’s CLUSTERSENSE initiative is integrating biosensors with closed-loop stimulators to reduce time-to-relief to under five minutes.In South Korea, reimbursement policies still require 12 months of failed oral prevention before coverage, delaying access to neuromodulation solutions.Scarcity of Headache Specialists & Diagnostic Delays
With only 564 board-certified headache specialists available, the U.S. faces a significant shortfall compared to the required 3,700 to 4,500. This shortage results in average wait times of 30 days for adults and delays of up to six months for pediatric patients. Misdiagnosis affects nearly half of the patients, extending their care pathway by six years and increasing emergency department visits. Rural Americans, facing longer travel distances, often journey 70 to 81 miles for specialist consultations, exacerbating existing socioeconomic disparities. While the HEADACHE Act aims to enhance telehealth funding, inconsistent reimbursement policies across states limit its adoption. Expanding the workforce alone may not be sufficient to drive CGRP mAb adoption without concurrent payer reforms and continuous education initiatives.Other drivers and restraints analyzed in the detailed report include:
- AI-Powered Wearable Headache-Diary Analytics
- Orphan-Drug Reimbursements & Rising Healthcare Spend
- Cardiovascular Safety Flags for Long-Acting CGRP mAbs
Segment Analysis
In 2025, imaging captured 41.23% of the cluster headache market, driven by the widespread use of MRI and CT scans to eliminate secondary causes. Biomarker assays, supported by ultra-rapid CGRP tests delivering results in just 32 minutes, are expected to grow at an annual rate of 8.10% through 2031, significantly reducing diagnostic delays. While clinical evaluations based on ICHD-3 criteria remain the primary diagnostic method, a 49% misdiagnosis rate highlights the critical need for objective biomarkers. Tear-fluid assays demonstrate resilience against preanalytical degradation, while genetic panels remain confined to research due to low penetrance and limited therapeutic applications.In 2025, acute treatments, led by oxygen and subcutaneous sumatriptan, accounted for 65.44% of the revenue. Preventive therapies are projected to grow at a 7.60% CAGR through 2031, as CGRP mAbs shift the clinical approach toward long-term attack suppression. Corticosteroid bridges and occipital nerve blocks serve as transitional solutions but lack the scale of acute and preventive segments. GammaCore's dual functionality in both acute and preventive treatment is driving interest in hybrid therapeutic strategies.
Complete Report Scope:
- By Diagnosis Type
- Clinical Assessment
- Imaging
- MRI
- CT
- Biomarker Assays
- Wearable Neuro-physiological Monitoring
- Genetic Testing
- By Treatment Type
- Acute Treatment
- Preventive Treatment
- Transitional Therapy
- By Drug Class
- Triptans
- CGRP Monoclonal Antibodies
- Ergot Alkaloids
- Calcium-Channel Blockers (Verapamil)
- Lithium Carbonate & Miscellaneous
- By Route of Administration
- Oral
- Injectable
- Intranasal
- Inhalation (Medical Oxygen)
- Neuromodulation Device
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- Home Healthcare Providers
- By Patient Type
- Episodic Cluster Headache
- Chronic Cluster Headache
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- Rest of Asia-Pacific
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America's cluster headache market benefits from extensive Medicare and commercial coverage for treatments such as galcanezumab and gammaCore. This advantage is further supported by a well-established network of specialists in metropolitan areas. However, rural regions continue to face significant challenges in accessing care. The implementation of the HEADACHE Act could allocate funding to telehealth initiatives, aiming to address these geographic disparities and improve access to treatment. Additionally, the United States is actively fostering innovation, as evidenced by the numerous investigator-initiated trials focusing on gepants. These developments highlight the region's commitment to advancing treatment options and addressing unmet needs in the market.In Europe, the market is driven by harmonized clinical guidelines and a strong emphasis on cost-effectiveness. The endorsement of vagus-nerve stimulation by regulatory bodies has influenced reimbursement policies across key markets, including Germany, France, and Nordic countries. Moreover, Europe is positioning itself as a leader in advanced medical technologies, with initiatives such as the development of AI-enabled closed-loop neuromodulation systems. These advancements are expected to enhance treatment outcomes, improve patient care, and drive the adoption of innovative solutions across the region.
The Asia-Pacific region is undergoing a transition from fragmented regulatory frameworks to unified standards under ASEAN and ICH guidelines. While South Korea's step-edit policies present barriers to the immediate adoption of biologics, Japan's stringent two-year post-marketing surveillance process generates robust safety data, fostering greater confidence in the long-term use of these treatments. In China, although CGRP monoclonal antibodies are not yet included in the National Reimbursement Drug List, pilot programs in select cities are exploring innovative value-based contracting models. These initiatives could pave the way for broader adoption and integration of advanced therapies, driving growth and improving patient outcomes in the region.
List of Companies Covered in this Report:
- Abbvie
- Amgen
- AstraZeneca
- Cipla
- Dr. Reddy’s Laboratories
- electroCore, Inc.
- Eli Lilly and Company
- Endo International
- GE HealthCare Technologies Inc.
- Hikma Pharmaceuticals
- Impel NeuroPharma, Inc.
- Johnson & Johnson
- Koninklijke Philips
- Lundbeck A/S
- Magstim Company Ltd.
- Nevro
- Novartis
- Otsuka
- Pfizer
- Salvia BioElectronics B.V.
- Satsuma Pharmaceuticals, Inc.
- Siemens Healthineers
- Teva Pharmaceutical Industries
- UCB
- Upsher-Smith Laboratories
- WraSer Pharmaceuticals, LLC
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, USD)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca plc
- Cipla Ltd.
- Dr. Reddy's Laboratories Ltd.
- electroCore, Inc.
- Eli Lilly & Co.
- Endo International plc
- GE HealthCare Technologies Inc.
- Hikma Pharmaceuticals PLC
- Impel NeuroPharma, Inc.
- Johnson & Johnson (Janssen)
- Koninklijke Philips N.V.
- Lundbeck A/S
- Magstim Company Ltd.
- Nevro Corp.
- Novartis AG
- Otsuka Pharmaceutical Co., Ltd.
- Pfizer Inc.
- Salvia BioElectronics B.V.
- Satsuma Pharmaceuticals, Inc.
- Siemens Healthineers AG
- Teva Pharmaceutical Industries Ltd.
- UCB S.A.
- Upsher-Smith Laboratories, LLC
- WraSer Pharmaceuticals, LLC
